<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02609399</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00080405</org_study_id>
    <secondary_id>1 IDSEP150026-01-00</secondary_id>
    <secondary_id>1 IDSEP160031-01-00</secondary_id>
    <nct_id>NCT02609399</nct_id>
  </id_info>
  <brief_title>ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir</brief_title>
  <official_title>Influenza Therapeutic Trial: A Pilot Randomized Controlled Trial for Feasibility of Enrolling Subjects for Influenza Therapeutic Trials and Administering Influenza Antivirals in the Emergency Department to High Risk Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is designed to demonstrate the feasibility of utilizing Emergency
      Departments (EDs) as a primary site for subject enrollment in clinical trials evaluating
      influenza therapeutics, and to provide pilot data for future clinical trial design and
      planning.

      Primary Objective: To prospectively enroll high-risk subjects with laboratory-confirmed
      influenza into a randomized, open label study of oral versus IV influenza therapeutic to
      include symptom evaluation and outcome assessments.

      Secondary Objective 1: To identify influenza positive patients utilizing a previously
      established triage-based assessment and rapid testing algorithm for suspected influenza
      infection.

      Secondary Objective 2: To retrospectively evaluate all potentially eligible patients for
      potential enrollment biases.

      Secondary Objective 3: To create a repository of residual nasopharyngeal samples collected
      from ED patients with suspected influenza illness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: A Pilot Randomized Controlled Trial for Feasibility of Enrolling Subjects for
      Influenza Therapeutic Trials and Administering Influenza Antivirals in the Emergency
      Department to High Risk Subjects

      Population: Adults presenting to the emergency department (ED) with laboratory confirmed
      influenza who meet Centers for Disease Control and Prevention (CDC) criteria for antiviral
      treatment

      Informed consent: Written informed consent

      Number of Sites: 2 - large, urban, academically-affiliated, US EDs

      Study Duration: November 2015 - June 2018

      Subject Participation Duration: 4 weeks

      Description of Agent or Intervention: Subjects will be randomized to either oral
      (oseltamivir) or intravenous (IV) (peramivir) antiviral treatment.

      Description of Study Design: This is an open-label randomized controlled clinical trial in
      which subjects with influenza are randomized to either oral (oseltamivir) or IV (peramivir)
      antiviral treatment.

      Estimated Time to Complete Enrollment: Subject enrollment will occur over two influenza
      seasons (November 2015 - April 2016 and November 2016 - April 2017) or longer, at the
      Principal Investigator's discretion, based on influenza prevalence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2015</start_date>
  <completion_date type="Actual">May 31, 2018</completion_date>
  <primary_completion_date type="Actual">May 26, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Symptom Severity Score During the 2015-2016 Influenza Season for Symptom Domains as Assessed Using the Influenza-Patient Reported Outcome (FLU-PRO™) Questionnaire</measure>
    <time_frame>ED Enrollment Visit through Day 14 ( 2015-2016 influenza season)</time_frame>
    <description>Symptom evaluation during the 2015-2016 influenza season as recorded through FLU-PRO™: a daily diary developed to assess occurrence and severity of influenza symptoms.
Item responses:
Not at all
A little bit
Somewhat
Quite a bit
Very much</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Symptom Severity Score During the 2016-2017 Influenza Season for Symptom Domains as Assessed Using the FLU-PRO™ Questionnaire</measure>
    <time_frame>ED Enrollment Visit through Day 14 ( 2016-2017 influenza season)</time_frame>
    <description>Symptom evaluation during the 2016-2017 influenza season as recorded through FLU-PRO™: a daily diary developed to assess occurrence and severity of influenza symptoms.
Item responses:
Not at all
A little bit
Somewhat
Quite a bit
Very much</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Karnofsky Performance Scale Score During the 2015-2016 Influenza Season</measure>
    <time_frame>ED Enrollment Visit through Day 14 ( 2015-2016 influenza season)</time_frame>
    <description>The Karnofsky Performance Scale is a tool for assessing subject functional impairment.
Subjects provided or received (from a healthcare provider such as a doctor or nurse) a daily rating from 0 (Dead) to 100 (Normal - no complaints, no evidence of disease) from enrollment through Day 14 of the 2015-2016 influenza season.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Karnofsky Performance Scale Score During the 2016-2017 Influenza Season</measure>
    <time_frame>ED Enrollment Visit through Day 14 ( 2016-2017 influenza season)</time_frame>
    <description>The Karnofsky Performance Scale is a tool for assessing subject functional impairment.
Subjects provided or received (from a healthcare provider such as a doctor or nurse) a daily rating from 0 (Dead) to 100 (Normal - no complaints, no evidence of disease) from enrollment through Day 14 of the 2016-2017 influenza season.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Oseltamivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the oral treatment arm will receive 5 days of oral oseltamivir.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peramivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the IV treatment group will receive 1 dose of IV peramivir.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>Oral</description>
    <arm_group_label>Oseltamivir</arm_group_label>
    <other_name>Tamiflu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peramivir</intervention_name>
    <description>IV
Note: Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician.</description>
    <arm_group_label>Peramivir</arm_group_label>
    <other_name>Rapivab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible patients include all patients who present to the emergency department (ED)
             between November and April of each influenza season, or later, at the Co-PIs'
             discretion, based on influenza prevalence, with the following criteria:

               1. 18 years of age or older

               2. Laboratory confirmed positive influenza test associated with their current ED
                  visit

               3. Symptoms of acute respiratory illness for ≤4 days (96 hours)

               4. Meets CDC criteria for antiviral treatment

          -  For the purpose of this study, acute respiratory illness is defined as presence of any
             of the following symptoms: new or increased cough, new or increased shortness of
             breath, change in sputum production (for adults 65 years or older), sinus pain, nasal
             congestion, rhinorrhea, sore throat, subjective fever reported at time of triage or
             documented fever (defined here as ≥ 38 degrees Celsius).

          -  CDC criteria for influenza antiviral treatment is defined as: being age 65 years old
             or older, pregnant or less than two weeks postpartum, American Indian or Alaska
             native, morbid obesity (BMI ≥40), a current resident of nursing home or other
             chronic-care facility, having chronic pulmonary disease, cardiovascular disease
             (except hypertension alone), renal disease, hepatic disease, hematologic disease,
             metabolic disorders, neurologic and neurodevelopment conditions, immunosuppression
             (including that caused by medications or by HIV infection), being admitted to
             inpatient or an observation unit, or having a clinical diagnosis of pneumonia (by the
             ED physician).

        Exclusion Criteria:

          1. Does not speak and understand English (or English or Spanish)

          2. Unable or unwilling to provide informed consent

          3. Previously enrolled in the study during the current influenza season

          4. Unable to take oral medication

          5. Unable to comply with all planned study procedures including availability for
             follow-up and willingness to complete study diary and self-assessment

          6. Use of neuraminidase inhibitors within the past seven days

          7. Known allergic reaction to neuraminidase inhibitors

          8. Pregnant or breastfeeding

          9. End-stage renal disease, defined as 9a. Currently undergoing dialysis (either hemo or
             peritoneal); or 9b. Creatinine clearance (CrCl) of &lt;10 mL/min.

         10. End-stage liver disease, as determined by the treating ED provider

         11. Glucose-6-phosphate dehydrogenase (G6PD) deficiency by patient report

         12. Immunodeficiency, defined as:

        12a. Solid organ transplant patients receiving immunosuppression; 12b. Hematopoietic stem
        cell transplant patients within 12 months of transplant or with ongoing immunosuppression;
        12c. Oncology patients who have had chemotherapy within the past 30 days; 12d. Current
        treatment with steroids equivalent to 10 mg of prednisone or more per day for greater than
        two weeks; 12e. Rheumatologic patients receiving immunosuppressive therapy; or 12f. HIV
        patients who meet one of the following criteria: 12fi. Have a cluster of differentiation 4
        (CD4) cell count of &lt;200 cells/mm3 within the past 3 months ; 12fii. Not actively receiving
        highly active antiretroviral therapy (HAART); or 12fiii. Have an absolute lymphocyte count
        &lt;1.0 x 103 cells/μL conducted at the current ED visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Rothman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maricopa Integrated Health System</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 27, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <results_first_submitted>April 11, 2018</results_first_submitted>
  <results_first_submitted_qc>May 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 20, 2018</results_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Antiviral treatment</keyword>
  <keyword>Emergency department</keyword>
  <keyword>Influenza therapeutics</keyword>
  <keyword>Rapid influenza testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
    <mesh_term>Peramivir</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 26, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02609399/Prot_SAP_ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study recruited adult patients through both clinical testing and screening with a Clinical Decision Guideline (CDG) over two influenza seasons at the following academically affiliated U.S. Emergency Departments (EDs):
November 2015- April 2016: Johns Hopkins Hospital (JHH)
November 2016- April 2017: JHH and Maricopa Medical Center (MMC)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Oseltamivir</title>
          <description>Subjects randomized to the oral treatment arm will receive 5 days of oral oseltamivir.</description>
        </group>
        <group group_id="P2">
          <title>Peramivir</title>
          <description>Subjects randomized to the IV treatment group will receive 1 dose of IV peramivir. (Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Influenza Season 2015-2016</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Influenza Season 2016-2017</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Found ineligible after randomization</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>For baseline analyses, overall characteristics (seasons 2015-2016 &amp; 2016-2017) &amp; characteristics stratified by influenza season (2015-2016 vs. 2016-2017) are presented. Total number of subjects contributing data to 2015-2016 baseline analyses was 58, compared to 121 subjects for 2016-2017 season. Information unavailable: 1 oseltamivir participant</population>
      <group_list>
        <group group_id="B1">
          <title>Experimental: Oseltamivir</title>
          <description>Subjects randomized to the oral treatment arm will receive 5 days of oral oseltamivir.</description>
        </group>
        <group group_id="B2">
          <title>Experimental: Peramivir</title>
          <description>Subjects randomized to the IV treatment group will receive 1 dose of IV peramivir.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
            <count group_id="B2" value="95"/>
            <count group_id="B3" value="179"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Baseline measures includes both influenza seasons 2015-2016 and 2016-2017. A total of 180 subjects were enrolled across both seasons. Baseline information is unavailable for 1 participant in the oseltamivir arm</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="95"/>
                    <count group_id="B3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.3" lower_limit="20" upper_limit="78"/>
                    <measurement group_id="B2" value="47.5" lower_limit="19" upper_limit="80"/>
                    <measurement group_id="B3" value="47.4" lower_limit="19" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Baseline measures includes both influenza seasons 2015-2016 and 2016-2017. A total of 180 subjects were enrolled across both seasons. Baseline information is unavailable for 1 participant in the oseltamivir arm</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="95"/>
                    <count group_id="B3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>Baseline measures includes both influenza seasons 2015-2016 and 2016-2017. A total of 180 subjects were enrolled across both seasons. Baseline information is unavailable for 1 participant in the oseltamivir arm</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="95"/>
                    <count group_id="B3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Baseline measures includes both influenza seasons 2015-2016 and 2016-2017. A total of 180 subjects were enrolled across both seasons. Baseline information is unavailable for 1 participant in the oseltamivir arm</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="95"/>
                    <count group_id="B3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="95"/>
                    <count group_id="B3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Continuous (Influenza Season 2015-2016)</title>
          <population>This measure is specific to the 2015-2016 influenza season, during which 58 subjects were enrolled and analyzed.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.7" lower_limit="20" upper_limit="68"/>
                    <measurement group_id="B2" value="43.7" lower_limit="19" upper_limit="72"/>
                    <measurement group_id="B3" value="46" lower_limit="19" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Continuous (Influenza Season 2016-2017)</title>
          <population>This measure is specific to the 2016-2017 influenza season, during which 122 subjects were enrolled and analyzed. Baseline information is unavailable for 1 participant in the oseltamivir arm.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                    <count group_id="B2" value="64"/>
                    <count group_id="B3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.6" lower_limit="20" upper_limit="78"/>
                    <measurement group_id="B2" value="49.3" lower_limit="20" upper_limit="80"/>
                    <measurement group_id="B3" value="48.0" lower_limit="20" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male (Influenza Season 2015-2016)</title>
          <population>This measure is specific to the 2015-2016 influenza season, during which 58 subjects were enrolled and analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male (Influenza Season 2016-2017)</title>
          <population>This measure is specific to the 2016-2017 influenza season, during which 122 subjects were enrolled and analyzed. Baseline information is unavailable for 1 participant in the oseltamivir arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                    <count group_id="B2" value="64"/>
                    <count group_id="B3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB) (Influenza Season 2015-2016)</title>
          <population>This measure is specific to the 2015-2016 influenza season, during which 58 subjects were enrolled and analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB) (Influenza Season 2016-2017)</title>
          <population>This measure is specific to the 2016-2017 influenza season, during which 122 subjects were enrolled and analyzed. Baseline information is unavailable for 1 participant in the oseltamivir arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                    <count group_id="B2" value="64"/>
                    <count group_id="B3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB) (Influenza Season 2015-2016)</title>
          <population>This measure is specific to the 2015-2016 influenza season, during which 58 subjects were enrolled and analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB) (Influenza Season 2016-2017)</title>
          <population>This measure is specific to the 2016-2017 influenza season, during which 122 subjects were enrolled and analyzed. Baseline information is unavailable for 1 participant in the oseltamivir arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                    <count group_id="B2" value="64"/>
                    <count group_id="B3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Symptom Severity Score During the 2015-2016 Influenza Season for Symptom Domains as Assessed Using the Influenza-Patient Reported Outcome (FLU-PRO™) Questionnaire</title>
        <description>Symptom evaluation during the 2015-2016 influenza season as recorded through FLU-PRO™: a daily diary developed to assess occurrence and severity of influenza symptoms.
Item responses:
Not at all
A little bit
Somewhat
Quite a bit
Very much</description>
        <time_frame>ED Enrollment Visit through Day 14 ( 2015-2016 influenza season)</time_frame>
        <population>All subjects enrolled and randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir</title>
            <description>Subjects randomized to the oral treatment arm will receive 5 days of oral oseltamivir.</description>
          </group>
          <group group_id="O2">
            <title>Peramivir</title>
            <description>Subjects randomized to the IV treatment group will receive 1 dose of IV peramivir. (Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Symptom Severity Score During the 2015-2016 Influenza Season for Symptom Domains as Assessed Using the Influenza-Patient Reported Outcome (FLU-PRO™) Questionnaire</title>
          <description>Symptom evaluation during the 2015-2016 influenza season as recorded through FLU-PRO™: a daily diary developed to assess occurrence and severity of influenza symptoms.
Item responses:
Not at all
A little bit
Somewhat
Quite a bit
Very much</description>
          <population>All subjects enrolled and randomized.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.8"/>
                    <measurement group_id="O2" value="1.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.8"/>
                    <measurement group_id="O2" value="1.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.6"/>
                    <measurement group_id="O2" value="1.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest/Respiratory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.2"/>
                    <measurement group_id="O2" value="2.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.1"/>
                    <measurement group_id="O2" value="1.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body/Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.2"/>
                    <measurement group_id="O2" value="1.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total/Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.1"/>
                    <measurement group_id="O2" value="1.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Symptom Severity Score During the 2016-2017 Influenza Season for Symptom Domains as Assessed Using the FLU-PRO™ Questionnaire</title>
        <description>Symptom evaluation during the 2016-2017 influenza season as recorded through FLU-PRO™: a daily diary developed to assess occurrence and severity of influenza symptoms.
Item responses:
Not at all
A little bit
Somewhat
Quite a bit
Very much</description>
        <time_frame>ED Enrollment Visit through Day 14 ( 2016-2017 influenza season)</time_frame>
        <population>All enrolled and randomized subjects with the exception of 1 inadvertent enrollment (subject found to be ineligible shortly after randomization)</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir</title>
            <description>Subjects randomized to the oral treatment arm will receive 5 days of oral oseltamivir.</description>
          </group>
          <group group_id="O2">
            <title>Peramivir</title>
            <description>Subjects randomized to the IV treatment group will receive 1 dose of IV peramivir. (Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Symptom Severity Score During the 2016-2017 Influenza Season for Symptom Domains as Assessed Using the FLU-PRO™ Questionnaire</title>
          <description>Symptom evaluation during the 2016-2017 influenza season as recorded through FLU-PRO™: a daily diary developed to assess occurrence and severity of influenza symptoms.
Item responses:
Not at all
A little bit
Somewhat
Quite a bit
Very much</description>
          <population>All enrolled and randomized subjects with the exception of 1 inadvertent enrollment (subject found to be ineligible shortly after randomization)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.8"/>
                    <measurement group_id="O2" value="1.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.6"/>
                    <measurement group_id="O2" value="1.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.7"/>
                    <measurement group_id="O2" value="1.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest/Respiratory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.8"/>
                    <measurement group_id="O2" value="1.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.7"/>
                    <measurement group_id="O2" value="1.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body/Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.8"/>
                    <measurement group_id="O2" value="1.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total/Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.6"/>
                    <measurement group_id="O2" value="1.5" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Karnofsky Performance Scale Score During the 2015-2016 Influenza Season</title>
        <description>The Karnofsky Performance Scale is a tool for assessing subject functional impairment.
Subjects provided or received (from a healthcare provider such as a doctor or nurse) a daily rating from 0 (Dead) to 100 (Normal - no complaints, no evidence of disease) from enrollment through Day 14 of the 2015-2016 influenza season.</description>
        <time_frame>ED Enrollment Visit through Day 14 ( 2015-2016 influenza season)</time_frame>
        <population>All subjects enrolled and randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Oseltamivir</title>
            <description>Subjects randomized to the oral treatment arm received 5 days of oral oseltamivir.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: Peramivir</title>
            <description>Subjects randomized to the IV treatment group will receive 1 dose of IV peramivir. (Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Karnofsky Performance Scale Score During the 2015-2016 Influenza Season</title>
          <description>The Karnofsky Performance Scale is a tool for assessing subject functional impairment.
Subjects provided or received (from a healthcare provider such as a doctor or nurse) a daily rating from 0 (Dead) to 100 (Normal - no complaints, no evidence of disease) from enrollment through Day 14 of the 2015-2016 influenza season.</description>
          <population>All subjects enrolled and randomized.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1" spread="20.8"/>
                    <measurement group_id="O2" value="73.2" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Karnofsky Performance Scale Score During the 2016-2017 Influenza Season</title>
        <description>The Karnofsky Performance Scale is a tool for assessing subject functional impairment.
Subjects provided or received (from a healthcare provider such as a doctor or nurse) a daily rating from 0 (Dead) to 100 (Normal - no complaints, no evidence of disease) from enrollment through Day 14 of the 2016-2017 influenza season.</description>
        <time_frame>ED Enrollment Visit through Day 14 ( 2016-2017 influenza season)</time_frame>
        <population>All enrolled and randomized subjects with the exception of 1 inadvertent enrollment (subject found to be ineligible shortly after randomization)</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Oseltamivir</title>
            <description>Subjects randomized to the oral treatment arm received 5 days of oral oseltamivir.</description>
          </group>
          <group group_id="O2">
            <title>Experimental: Peramivir</title>
            <description>Subjects randomized to the IV treatment group will receive 1 dose of IV peramivir. (Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Karnofsky Performance Scale Score During the 2016-2017 Influenza Season</title>
          <description>The Karnofsky Performance Scale is a tool for assessing subject functional impairment.
Subjects provided or received (from a healthcare provider such as a doctor or nurse) a daily rating from 0 (Dead) to 100 (Normal - no complaints, no evidence of disease) from enrollment through Day 14 of the 2016-2017 influenza season.</description>
          <population>All enrolled and randomized subjects with the exception of 1 inadvertent enrollment (subject found to be ineligible shortly after randomization)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" spread="10.7"/>
                    <measurement group_id="O2" value="79.9" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Accrual for the 2015-2016 influenza season opened on 11/1/2015 and closed on 4/30/2016. Accrual for the 2016-2017 influenza season opened on 11/1/2016 and closed on 4/30/2017. All enrolled participants were assessed for adverse events from enrollment visit until the end of study follow up on Day 28.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oseltamivir</title>
          <description>Subjects randomized to the oral treatment arm will receive 5 days of oral oseltamivir.
Oseltamivir: Oral</description>
        </group>
        <group group_id="E2">
          <title>Peramivir</title>
          <description>Subjects randomized to the IV treatment group will receive 1 dose (or more as appropriate at the discretion of the treating physician) of IV peramivir.
Peramivir: IV
Note: Should a patient remain in the hospital after 5 days of treatment, and the patient is symptomatically better, treatment will stop. If the patient remains hospitalized after 5 days of treatment and has not improved, the treating physician will continue to have an option to continue use of peramivir daily for another 5 day course.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease (COPD)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pre-op admission</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="84"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="84"/>
                <counts group_id="E2" events="36" subjects_affected="31" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="84"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="84"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion/Hallucinations</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="84"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="84"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Not designed or powered to assess differences in clinical outcomes.
Planned to recruit &gt;= 50 subjects/site, but MMC enrolled 44 due to lower-than-expected flu incidence and Hopkins Uni. increased enrollment to make up for the shortfall.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Richard Rothman</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-735-6428</phone>
      <email>rrothma1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

